EXPERIENCE OF TREATING MULTIPLE AND EXTENSIVE DRUG RESISTANT TUBERCULOSIS WITH NEW REGIMENS IN BELARUS REPUBLIC
https://doi.org/10.21292/2075-1230-2018-96-8-5-14
Abstract
The objective of the study: to describe the efficiency and safety of new anti-tuberculosis drugs when treating tuberculosis patients with drug resistance.
Subjects and methods. In Belarus, the retrospective and prospective analyses were performed in the cohort of 300 patients with multiple drug resistance and high rates of extensive drug resistance, who were treated with new drugs and drugs which were started to be used for the treatment of tuberculosis. In order to describe the cohort, blocks of variables were used to specify the efficiency and safety profiles of new anti-tuberculosis drugs.
Results of the study. The high level of therapeutic efficiency of new regimens and their fairly favorable safety profile were demonstrated in the cohort.
About the Authors
E. M. Skryagina
Republican Scientific Practical Center of Pulmonology and Phthisiology.
Russian Federation
Russian Federation
Elena M. Skryagina Doctor of Medical Sciences, Deputy Director for Research.
157, Dolginovsky Road, Minsk, 220053.
G. L. Gurevich
Republican Scientific Practical Center of Pulmonology and Phthisiology.
Russian Federation
Russian Federation
Gennady L. Gurevich Doctor of Medical Sciences, Professor, Correspondent Member of National Academy of Belarus, Director.
157, Dolginovsky Road, Minsk, 220053.
V. V. Solodovnikova
Republican Scientific Practical Center of Pulmonology and Phthisiology.
Russian Federation
Russian Federation
Varvara V. Solodovnikova Senior Researcher of Department for Tuberculosis Laboratory Diagnostics and Treatment.
157, Dolginovsky Road, Minsk, 220053.
M. I. Dyusmikeeva
Republican Scientific Practical Center of Pulmonology and Phthisiology.
Russian Federation
Russian Federation
Marina I. Dyusmikeeva Candidate of Medical Sciences, Associate Professor, Morbid Anatomist, Head of Autopsy Department.
157, Dolginovsky Road, Minsk, 220053.
S. B. Setkina
Center for Examinations and Tests in Health Service.
Russian Federation
Russian Federation
Svetlana B. Setkina Deputy Head of Republican Clinical Pharmacological Laboratory.
2a, Tovarischesky Lane, Apt. 202, Minsk.
D. M. Zhurkin
Belorussian State Medical University.
Russian Federation
Russian Federation
Dmitry M. Zhurkin Assistant of Phthisiopulmonology Department.
157, Dolginovsky Road, Minsk, 220053.
References
1. Edict no. 601 by the Ministry of Health of Belarus as of 30.05.2017. Clinical guidelines on diagnostics and treatment of tuberculosis an its drug resistant forms.
2. Active tuberculosis drug safety monitoring and management (aDSM). Framework for implementation. World Health Organization, 2015, 20 p.
3. CHMP assessment report SIRTURO. International non-proprietary name: bedaquiline Procedure No. EMEA/H/C/002614/0000. EMA, 2013, 107 p.
4. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0 Published: May 28, 2009 (v4.03: June 14, 2010), U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institutes of Health National Cancer Institute. 196 p.
5. Review of available evidence on the use of bedaquiline for the treatment of multidrug-resistant tuberculosis: data analysis report. Version 6. L. Mbuagbaw for WHO. World Health Organization, 2017, 41 p.
6. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim Police Guidance. World Health Organization, 2013, 64 p.
7. WHO treatment guidelines for drug-resistant tuberculosis. 2016 Update. World Health Organization, 2016, 56 p.
Review
For citations:
Skryagina E.M., Gurevich G.L., Solodovnikova V.V., Dyusmikeeva M.I., Setkina S.B., Zhurkin D.M. EXPERIENCE OF TREATING MULTIPLE AND EXTENSIVE DRUG RESISTANT TUBERCULOSIS WITH NEW REGIMENS IN BELARUS REPUBLIC. Tuberculosis and Lung Diseases. 2018;96(8):5-14. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-8-5-14
Views:
1299
Email this article 